摘要
肝癌是消化系统最常见的恶性肿瘤之一。肺癌、肝癌、胃癌、乳腺癌和结肠癌是癌症相关死亡的前五大主要原因,其中肝癌从2018年的第三高癌症死亡率上升到2020年的第二高。越来越多的证据表明全身炎症反应与癌症患者的预后有密切的关系,并且血清学的检查,相比于其他的检测手段来说更加简便、花费更小,因此血清炎症因子也得到了人们的广泛关注,其中最具代表性的是中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio, NLR)和血小板与淋巴细胞比值(platelet to lym-phocyte ratio, PLR)。NLR和PLR与肝癌的相关性研究已在各个阶段展开,全文就其在肝癌治疗预后中的临床作用进行综述。
Liver cancer is one of the most common malignant tumors of digestive system. Lung, liver, stomach, breast and colon cancers are the top five leading causes of cancer-related deaths, with liver cancer rising from the third highest cancer death rate in 2018 to the second highest in 2020. More and more evidence shows that systemic inflammatory response is closely related to the prognosis of cancer patients, and serological tests are more convenient and less costly than other detection methods, so serum inflammatory factors have attracted wide attention, among which the most rep-resentative ones are neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR). Studies on the correlation between NLR and PLR and liver cancer have been carried out at various stages. This paper reviews the clinical effects of NLR and PLR in the treatment and prognosis of liver cancer.
出处
《临床医学进展》
2023年第8期12552-12558,共7页
Advances in Clinical Medicine
